STAAR Surgical advances EVO ICL adoption as FDA approval reframes high-myopia treatment economics
FDA expands EVO ICL use to ages 21–60. Discover what this means for refractive surgery, safety data, and the shift away from laser vision correction.
Medical Devices & Diagnostics